dipyridamole has been researched along with Active Hyperemia in 74 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed the safety of early (2 to 4 days) intravenous dipyridamole infusion in conjunction with technetium 99m sestamibi tomographic myocardial perfusion imaging in patients with first myocardial infarction (MI)." | 9.08 | Safety of early intravenous dipyridamole technetium 99m sestamibi SPECT myocardial perfusion imaging after uncomplicated first myocardial infarction. Early Post MI IV Dipyridamole Study (EPIDS). ( Brown, KA; Haber, SB; Heller, GV; Landin, RJ, 1997) |
| " For studies on the interactions of the substances with coronary hyperemia, broad search terms such as "caffeine AND adenosine" were applied in the major research data bases." | 8.85 | Effects of caffeine and theophylline on coronary hyperemia induced by adenosine or dipyridamole. ( Kern, MJ; Salcedo, J, 2009) |
| " Temporary myocardial ischemia and dipyridamole administration both result in increased coronary blood flow, but by different mechanisms." | 8.82 | Reactive hyperemia following coronary balloon angioplasty, but not dipyridamole-induced hyperemia, predicts resolution of exercise-induced ST-segment depression. ( Biro, S; Hamasaki, S; Ishida, S; Kamekou, M; Kataoka, T; Minagoe, S; Nakano, F; Saihara, K; Tei, C; Tsurugida, M; Yoshikawa, A; Yoshitama, T, 2003) |
| "With the standard timing protocol from the package insert, regadenoson achieved only 80% of dipyridamole hyperemia quantitatively imaged by cardiac positron emission tomography using Rb-82." | 7.81 | Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. ( Gould, KL; Johnson, NP, 2015) |
| "The goal of this study was to examine the relationship between plasma asymmetric dimethylarginine (ADMA) level and hyperemic myocardial blood flow (MBF) in subjects with borderline hypertension (BHT) and familial hypercholesterolemia (FH)." | 7.71 | Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. ( Knuuti, J; Laakso, J; Laaksonen, R; Laine, H; Päivä, H; Raitakari, OT, 2002) |
| " Pharmacologic hyperemia with dipyridamole is now used routinely in such patients for detection of significant coronary artery disease." | 7.70 | Prognostic value of myocardial perfusion imaging with exercise and/or dipyridamole hyperemia in patients with preexisting left bundle branch block. ( Humen, DP; Nigam, A, 1998) |
| "Dipyridamole-induced coronary hyperemia produces mild hemodynamic changes in patients with and without CAD; these changes are at or near peak effect at 3 min after infusion and are rapidly reversed by aminophylline." | 7.70 | Correlation between hemodynamic changes and tomographic sestamibi imaging during dipyridamole-induced coronary hyperemia. ( Heo, J; Iskandrian, AE; Kegel, JG; Ogilby, JD, 1998) |
| "This study sought to investigate the specific role of hypertriglyceridemia in the myocardial hyperemic stress with dipyridamole/rest flow ratio (MDR)." | 7.70 | Impaired myocardial vasodilation during hyperemic stress with dipyridamole in hypertriglyceridemia. ( Momomura, S; Nishikawa, J; Ohtake, T; Omata, M; Sasaki, Y; Yokoyama, I; Yonekura, K, 1998) |
| "The role of adenosine in postprandial jejunal hyperemia was investigated by determining the effect of placement of predigested food into the jejunal lumen on blood flow and oxygen consumption before and during intra-arterial infusion of dipyridamole (1." | 7.68 | Role of adenosine in postprandial and reactive hyperemia in canine jejunum. ( Chou, CC; Sawmiller, DR, 1992) |
| "The effects of dipyridamole on active hyperemia were evaluated in dog gracilis muscles undergoing sustained isometric contractions." | 7.67 | Conditions for dipyridamole potentiation of skeletal muscle active hyperemia. ( Klabunde, RE, 1986) |
| "To determine the myocardial kinetics of technetium-tertiary-butyl-isonitrile (Tc-TBI) during dipyridamole-induced hyperemia, the circumflex coronary arteries (LCX) of 15 dogs were partially occluded." | 7.67 | Cardiac imaging and myocardial kinetics of technetium-tertiary butyl-isonitrile during dipyridamole-induced hyperemia. ( Dragatokis, D; Glover, DK; Okada, RD; Williams, SJ, 1988) |
| "We measured myocardial blood flow (MBF) with a PET scan at rest, during cold pressor testing (CPT), and during dipyridamole hyperemia in 54 postmenopausal women without coronary artery disease." | 5.10 | Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration. ( Campisi, R; Chaudhuri, G; Nathan, L; Pampaloni, MH; Sayre, JW; Schelbert, HR; Schöder, H, 2002) |
| "We assessed the safety of early (2 to 4 days) intravenous dipyridamole infusion in conjunction with technetium 99m sestamibi tomographic myocardial perfusion imaging in patients with first myocardial infarction (MI)." | 5.08 | Safety of early intravenous dipyridamole technetium 99m sestamibi SPECT myocardial perfusion imaging after uncomplicated first myocardial infarction. Early Post MI IV Dipyridamole Study (EPIDS). ( Brown, KA; Haber, SB; Heller, GV; Landin, RJ, 1997) |
| " For studies on the interactions of the substances with coronary hyperemia, broad search terms such as "caffeine AND adenosine" were applied in the major research data bases." | 4.85 | Effects of caffeine and theophylline on coronary hyperemia induced by adenosine or dipyridamole. ( Kern, MJ; Salcedo, J, 2009) |
| " Temporary myocardial ischemia and dipyridamole administration both result in increased coronary blood flow, but by different mechanisms." | 4.82 | Reactive hyperemia following coronary balloon angioplasty, but not dipyridamole-induced hyperemia, predicts resolution of exercise-induced ST-segment depression. ( Biro, S; Hamasaki, S; Ishida, S; Kamekou, M; Kataoka, T; Minagoe, S; Nakano, F; Saihara, K; Tei, C; Tsurugida, M; Yoshikawa, A; Yoshitama, T, 2003) |
| "Our results suggest that dipyridamole and regadenoson induce equivalent hyperemia in dynamic SPECT with similar stress MBF and MFR in comparable patients." | 4.12 | Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera. ( Angoulvant, D; Bailly, M; Brana, Q; Courtehoux, M; Metrard, G; Ribeiro, MJ; Thibault, F, 2022) |
| "In 16 patients with chest pain and angiographically normal coronary arteries, CFR was measured using transthoracic echo-Doppler by inducing hyperemia through dipyridamole infusion." | 3.85 | Coronary flow reserve/diastolic function relationship in angina-suffering patients with normal coronary angiography. ( Anchisi, C; Bellacosa, I; Grossini, E; Marino, P; Marti, G; Mary, D; Vacca, G, 2017) |
| "With the standard timing protocol from the package insert, regadenoson achieved only 80% of dipyridamole hyperemia quantitatively imaged by cardiac positron emission tomography using Rb-82." | 3.81 | Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. ( Gould, KL; Johnson, NP, 2015) |
| "Maximal wall thickness was identified as the strongest predictor of impaired dipyridamole-induced hyperemia and flow reserve in our study, whereas outflow tract obstruction was not an independent determinant." | 3.78 | PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy. ( Abraham, MR; Abraham, TP; Bengel, FM; Bravo, PE; Higuchi, T; Merrill, J; Pinheiro, A; Rischpler, C; Santaularia-Tomas, M; Wahl, RL, 2012) |
| "This study aimed to determine the quantitative low-flow threshold for stress-induced perfusion defects with severe angina and/or significant ST-segment depression during dipyridamole hyperemia." | 3.77 | Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve. ( Gould, KL; Johnson, NP, 2011) |
| "Twenty-one beagles and small mongrel dogs without coronary artery stenosis (controls) or with moderate to severe acute coronary artery stenosis underwent MRI and PET imaging at rest and during dipyridamole vasodilation or dobutamine stress to induce a wide range of changes in cardiac perfusion and oxygenation." | 3.76 | Quantification of regional myocardial oxygenation by magnetic resonance imaging: validation with positron emission tomography. ( Abendschein, DR; Goldstein, TA; Gropler, RJ; Herrero, P; McCommis, KS; Misselwitz, B; Zheng, J, 2010) |
| "In 34 patients with HCM, PET was performed using (13)N-labeled ammonia during hyperemia induced by intravenous dipyridamole." | 3.74 | Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy. ( Betti, I; Camici, PG; Casolo, G; Cecchi, F; Olivotto, I; Pupi, A; Rega, L; Sciagrà, R; Sotgia, B, 2008) |
| " Myocardial blood flow (MBF) was measured at rest and during adenosine or dipyridamole-induced hyperemia with positron emission tomography using [(15)O] H(2)O." | 3.73 | The influence of hepatic lipase C-480T polymorphism on coronary flow reserve in young men is independent of the plasma cholesterol level. ( Fan, YM; Janatuinen, T; Knuuti, J; Laaksonen, R; Laine, H; Lehtimäki, T; Nuutila, P; Raitakari, OT; Rontu, R; Vesalainen, R, 2006) |
| "This study demonstrates that ATP has the potential to induce greater hyperemia than dipyridamole, whereas hyperemic responses to ATP and dipyridamole are similarly attenuated after caffeine intake." | 3.72 | Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole. ( Kitano, H; Konishi, J; Kubo, S; Magata, Y; Mamede, M; Mukai, T; Tadamura, E; Tamaki, N; Toyoda, H; Yamamuro, M, 2004) |
| "The goal of this study was to examine the relationship between plasma asymmetric dimethylarginine (ADMA) level and hyperemic myocardial blood flow (MBF) in subjects with borderline hypertension (BHT) and familial hypercholesterolemia (FH)." | 3.71 | Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia. ( Knuuti, J; Laakso, J; Laaksonen, R; Laine, H; Päivä, H; Raitakari, OT, 2002) |
| "MBF was quantified by positron emission tomography with oxygen-15-labeled water at baseline and during hyperemia induced by either adenosine or dipyridamole in 131 men and 38 women, aged 21-86 (mean 46+/-12) years." | 3.71 | Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. ( Camici, PG; Chareonthaitawee, P; Kaufmann, PA; Rimoldi, O, 2001) |
| "Dipyridamole-induced coronary hyperemia produces mild hemodynamic changes in patients with and without CAD; these changes are at or near peak effect at 3 min after infusion and are rapidly reversed by aminophylline." | 3.70 | Correlation between hemodynamic changes and tomographic sestamibi imaging during dipyridamole-induced coronary hyperemia. ( Heo, J; Iskandrian, AE; Kegel, JG; Ogilby, JD, 1998) |
| " Pharmacologic hyperemia with dipyridamole is now used routinely in such patients for detection of significant coronary artery disease." | 3.70 | Prognostic value of myocardial perfusion imaging with exercise and/or dipyridamole hyperemia in patients with preexisting left bundle branch block. ( Humen, DP; Nigam, A, 1998) |
| "This study sought to investigate the specific role of hypertriglyceridemia in the myocardial hyperemic stress with dipyridamole/rest flow ratio (MDR)." | 3.70 | Impaired myocardial vasodilation during hyperemic stress with dipyridamole in hypertriglyceridemia. ( Momomura, S; Nishikawa, J; Ohtake, T; Omata, M; Sasaki, Y; Yokoyama, I; Yonekura, K, 1998) |
| "We studied 22 patients with IDC and 22 control subjects using PET with nitrogen-13 ammonia to measure myocardial blood flow (MBF) at rest and during dipyridamole-induced hyperemia." | 3.70 | Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. ( Blanksma, PK; Crijns, HJ; Siebelink, HM; Vaalburg, WM; van den Heuvel, AF; van der Wall, EE; van Gilst, WH; van Veldhuisen, DJ, 2000) |
| "The role of adenosine in postprandial jejunal hyperemia was investigated by determining the effect of placement of predigested food into the jejunal lumen on blood flow and oxygen consumption before and during intra-arterial infusion of dipyridamole (1." | 3.68 | Role of adenosine in postprandial and reactive hyperemia in canine jejunum. ( Chou, CC; Sawmiller, DR, 1992) |
| " During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography." | 3.68 | Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography. ( Bolli, R; Cheirif, J; Desir, RM; Mahmarian, JJ; Quiñones, MA; Verani, MS; Zoghbi, WA, 1992) |
| " Twenty-nine studies were performed at control, 13 during ischemia, eight after reperfusion, 13 during dipyridamole-induced hyperemia, and two during alteration of cardiac workload." | 3.68 | Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. ( Armbrecht, JJ; Buxton, DB; Schelbert, HR, 1990) |
| " The alterations of flow documented a horizontal epicardial steal induced during dipyridamole hyperemia, hyperemic flow reversal by intravenous aminophylline, and subsequent normalization of distal hyperemia after endoluminal enlargement by successful angioplasty." | 3.68 | Quantitative demonstration of dipyridamole-induced coronary steal and alteration by angioplasty in man: analysis by simultaneous, continuous dual Doppler spectral flow velocity. ( Aguirre, FV; Bach, RG; Caracciolo, EA; Donohue, TJ; Flynn, MS; Kern, MJ; Wolford, T, 1993) |
| "To determine the myocardial kinetics of technetium-tertiary-butyl-isonitrile (Tc-TBI) during dipyridamole-induced hyperemia, the circumflex coronary arteries (LCX) of 15 dogs were partially occluded." | 3.67 | Cardiac imaging and myocardial kinetics of technetium-tertiary butyl-isonitrile during dipyridamole-induced hyperemia. ( Dragatokis, D; Glover, DK; Okada, RD; Williams, SJ, 1988) |
| "Adenosine may be an important metabolic regulator of coronary blood flow during active hyperemia in the newborn." | 3.67 | Myocardial reactive hyperemia in the newborn. ( Ely, SW; Mainwaring, RD; Mentzer, RM, 1988) |
| " The present study was designed to compare coronary flow and resistance responses to intravenous dipyridamole and intracoronary injection of contrast medium (ioxaglate), this latter technique being frequently used in digital radiology to stimulate hyperemia." | 3.67 | Dipyridamole versus intracoronary injection of contrast medium for the evaluation of coronary reserve in man: a comparative study. ( Foult, JM; Nitenberg, A, 1986) |
| " N-13 ammonia was administered intravenously and its distribution in the left ventricular myocardium recorded at rest and during dipyridamole-induced coronary hyperemia." | 3.66 | Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI. Detection of coronary artery disease in human beings with intravenous N-13 ammonia and positron computed tomography. ( Gomes, A; Gould, KL; Henze, E; Hoffman, EJ; Kuhl, DE; Phelps, ME; Schelbert, HR; Wisenberg, G, 1982) |
| "In a dosage of 50 mg bid, eplerenone does not augment extracellular adenosine formation in healthy human subjects." | 2.79 | The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study. ( Bilos, A; Deinum, J; Donders, AR; Riksen, NP; Rongen, GA; van den Berg, TN, 2014) |
| "Diet-induced glucose intolerance is associated with impaired myocardial function during conditions of hyperaemia, but myocardial perfusion is maintained." | 1.38 | High fat diet-induced glucose intolerance impairs myocardial function, but not myocardial perfusion during hyperaemia: a pilot study. ( Boer, C; Bouwman, RA; Bulte, CS; Kloeze, BM; Loer, SA; van den Brom, CE, 2012) |
| "Dipyridamole was infused (0." | 1.35 | Detection of moderate regional ischemia in pig hearts in vivo by near-infrared and thermal imaging: effects of dipyridamole. ( Kupriyanov, VV; Manley, DM; Xiang, B, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (32.43) | 18.7374 |
| 1990's | 18 (24.32) | 18.2507 |
| 2000's | 19 (25.68) | 29.6817 |
| 2010's | 12 (16.22) | 24.3611 |
| 2020's | 1 (1.35) | 2.80 |
| Authors | Studies |
|---|---|
| Brana, Q | 1 |
| Thibault, F | 1 |
| Courtehoux, M | 1 |
| Metrard, G | 1 |
| Ribeiro, MJ | 1 |
| Angoulvant, D | 1 |
| Bailly, M | 1 |
| Jogiya, R | 1 |
| Makowski, M | 1 |
| Phinikaridou, A | 1 |
| Patel, AS | 1 |
| Jansen, C | 1 |
| Zarinabad, N | 1 |
| Chiribiri, A | 1 |
| Botnar, R | 1 |
| Nagel, E | 1 |
| Kozerke, S | 1 |
| Plein, S | 1 |
| van den Berg, TN | 1 |
| Deinum, J | 1 |
| Bilos, A | 1 |
| Donders, AR | 1 |
| Rongen, GA | 3 |
| Riksen, NP | 3 |
| Johnson, NP | 2 |
| Gould, KL | 3 |
| Sinusas, AJ | 1 |
| Dilsizian, V | 1 |
| Narula, J | 1 |
| Anchisi, C | 1 |
| Marti, G | 1 |
| Bellacosa, I | 1 |
| Mary, D | 1 |
| Vacca, G | 1 |
| Marino, P | 1 |
| Grossini, E | 1 |
| Sotgia, B | 1 |
| Sciagrà, R | 1 |
| Olivotto, I | 1 |
| Casolo, G | 1 |
| Rega, L | 1 |
| Betti, I | 1 |
| Pupi, A | 1 |
| Camici, PG | 3 |
| Cecchi, F | 1 |
| Salcedo, J | 1 |
| Kern, MJ | 3 |
| McCommis, KS | 3 |
| Zhang, H | 2 |
| Goldstein, TA | 3 |
| Misselwitz, B | 2 |
| Abendschein, DR | 2 |
| Gropler, RJ | 3 |
| Zheng, J | 3 |
| Herrero, P | 1 |
| Koktzoglou, I | 1 |
| Northrup, BE | 1 |
| Li, D | 1 |
| van Giezen, JJ | 1 |
| Sidaway, J | 1 |
| Glaves, P | 1 |
| Kirk, I | 1 |
| Björkman, JA | 1 |
| Bravo, PE | 1 |
| Pinheiro, A | 1 |
| Higuchi, T | 1 |
| Rischpler, C | 1 |
| Merrill, J | 1 |
| Santaularia-Tomas, M | 1 |
| Abraham, MR | 1 |
| Wahl, RL | 1 |
| Abraham, TP | 1 |
| Bengel, FM | 1 |
| van den Brom, CE | 1 |
| Bulte, CS | 1 |
| Kloeze, BM | 1 |
| Loer, SA | 1 |
| Boer, C | 1 |
| Bouwman, RA | 1 |
| Päivä, H | 1 |
| Laakso, J | 1 |
| Laine, H | 2 |
| Laaksonen, R | 2 |
| Knuuti, J | 3 |
| Raitakari, OT | 3 |
| Kofoed, KF | 1 |
| Hove, JD | 1 |
| Freiberg, J | 1 |
| Høst, U | 1 |
| Holm, S | 1 |
| Kelbaek, H | 2 |
| Saihara, K | 1 |
| Hamasaki, S | 1 |
| Biro, S | 1 |
| Kamekou, M | 1 |
| Nakano, F | 1 |
| Tsurugida, M | 1 |
| Yoshitama, T | 1 |
| Ishida, S | 1 |
| Yoshikawa, A | 1 |
| Kataoka, T | 1 |
| Minagoe, S | 1 |
| Tei, C | 1 |
| Stolen, KQ | 1 |
| Kemppainen, J | 1 |
| Kalliokoski, KK | 1 |
| Karanko, H | 1 |
| Toikka, J | 1 |
| Janatuinen, T | 2 |
| Airaksinen, KE | 1 |
| Nuutila, P | 2 |
| Kubo, S | 1 |
| Tadamura, E | 1 |
| Toyoda, H | 1 |
| Mamede, M | 1 |
| Yamamuro, M | 1 |
| Magata, Y | 1 |
| Mukai, T | 1 |
| Kitano, H | 1 |
| Tamaki, N | 1 |
| Konishi, J | 1 |
| Moir, S | 1 |
| Haluska, BA | 1 |
| Jenkins, C | 1 |
| Fathi, R | 1 |
| Marwick, TH | 1 |
| Fan, YM | 1 |
| Vesalainen, R | 1 |
| Rontu, R | 1 |
| Lehtimäki, T | 1 |
| Martin, EA | 1 |
| Nicholson, WT | 1 |
| Curry, TB | 1 |
| Eisenach, JH | 1 |
| Charkoudian, N | 1 |
| Joyner, MJ | 1 |
| Franke, B | 1 |
| Oyen, WJ | 1 |
| Borm, GF | 1 |
| van den Broek, P | 1 |
| Boerman, OC | 1 |
| Smits, P | 2 |
| Kupriyanov, VV | 1 |
| Manley, DM | 1 |
| Xiang, B | 1 |
| Meijer, P | 1 |
| Wouters, CW | 1 |
| van den Broek, PH | 1 |
| Scheffer, GJ | 1 |
| Schelbert, HR | 5 |
| Wisenberg, G | 1 |
| Phelps, ME | 2 |
| Henze, E | 1 |
| Hoffman, EJ | 1 |
| Gomes, A | 1 |
| Kuhl, DE | 1 |
| Chilian, WM | 2 |
| Marcus, ML | 2 |
| Granger, HJ | 1 |
| Norris, CP | 1 |
| Czernin, J | 2 |
| Auerbach, M | 1 |
| Sun, KT | 2 |
| Phelps, M | 1 |
| Wolford, T | 1 |
| Donohue, TJ | 1 |
| Bach, RG | 1 |
| Aguirre, FV | 1 |
| Caracciolo, EA | 1 |
| Flynn, MS | 1 |
| Wilke, N | 1 |
| Simm, C | 1 |
| Zhang, J | 1 |
| Ellermann, J | 1 |
| Ya, X | 1 |
| Merkle, H | 1 |
| Path, G | 1 |
| Lüdemann, H | 1 |
| Bache, RJ | 1 |
| Uğurbil, K | 1 |
| Niemi, P | 1 |
| Poncelet, BP | 1 |
| Kwong, KK | 1 |
| Weisskoff, RM | 1 |
| Rosen, BR | 1 |
| Brady, TJ | 2 |
| Kantor, HL | 2 |
| Nagamachi, S | 1 |
| Kim, AS | 1 |
| Böttcher, M | 1 |
| Lorenzoni, R | 1 |
| Rosen, SD | 1 |
| Heller, GV | 1 |
| Brown, KA | 2 |
| Landin, RJ | 1 |
| Haber, SB | 1 |
| Ogilby, JD | 1 |
| Kegel, JG | 1 |
| Heo, J | 1 |
| Iskandrian, AE | 1 |
| Nigam, A | 1 |
| Humen, DP | 1 |
| Yokoyama, I | 1 |
| Ohtake, T | 1 |
| Momomura, S | 1 |
| Yonekura, K | 1 |
| Nishikawa, J | 1 |
| Sasaki, Y | 1 |
| Omata, M | 1 |
| Caiati, C | 1 |
| Montaldo, C | 1 |
| Zedda, N | 1 |
| Bina, A | 1 |
| Iliceto, S | 1 |
| van den Heuvel, AF | 1 |
| van Veldhuisen, DJ | 1 |
| van der Wall, EE | 1 |
| Blanksma, PK | 1 |
| Siebelink, HM | 1 |
| Vaalburg, WM | 1 |
| van Gilst, WH | 1 |
| Crijns, HJ | 1 |
| Germain, P | 1 |
| Roul, G | 1 |
| Baruthio, J | 1 |
| Jahn, C | 1 |
| Coulbois, PM | 1 |
| Dumitresco, B | 1 |
| Dietemann, JL | 1 |
| Bareiss, P | 1 |
| Constantinesco, A | 1 |
| Chareonthaitawee, P | 1 |
| Kaufmann, PA | 1 |
| Rimoldi, O | 1 |
| Auer, J | 1 |
| Robert, B | 1 |
| Eber, B | 1 |
| Campisi, R | 1 |
| Nathan, L | 1 |
| Pampaloni, MH | 1 |
| Schöder, H | 1 |
| Sayre, JW | 1 |
| Chaudhuri, G | 1 |
| Degenring, FH | 1 |
| Curnish, RR | 1 |
| Rubio, R | 1 |
| Berne, RM | 1 |
| Maul, E | 1 |
| Sears, M | 1 |
| Yamazaki, H | 1 |
| Aya, S | 1 |
| Horikawa, M | 1 |
| Matsumura, N | 1 |
| Nakamura, Y | 1 |
| Sawmiller, DR | 1 |
| Chou, CC | 1 |
| Iskandrian, AS | 1 |
| Cheirif, J | 2 |
| Desir, RM | 1 |
| Bolli, R | 2 |
| Mahmarian, JJ | 1 |
| Zoghbi, WA | 2 |
| Verani, MS | 1 |
| Quiñones, MA | 2 |
| Aguirre, F | 1 |
| Donohue, T | 1 |
| Bach, R | 1 |
| Houghton, JL | 1 |
| Carr, AA | 1 |
| Frank, MJ | 1 |
| Armbrecht, JJ | 1 |
| Buxton, DB | 1 |
| Slinker, BK | 1 |
| Wangler, RD | 1 |
| Peters, KG | 1 |
| Tomanek, RJ | 1 |
| O'Neill, PG | 1 |
| Hoyt, BD | 1 |
| Miller, DD | 1 |
| Holmvang, G | 1 |
| Gill, JB | 2 |
| Dragotakes, D | 1 |
| Okada, RD | 3 |
| Williams, SJ | 1 |
| Glover, DK | 1 |
| Dragatokis, D | 1 |
| Madsen, PV | 1 |
| Munck, O | 1 |
| Mainwaring, RD | 1 |
| Ely, SW | 1 |
| Mentzer, RM | 1 |
| Ruddy, TD | 1 |
| Finkelstein, DM | 1 |
| Strauss, HW | 1 |
| McKusick, KA | 1 |
| Boucher, CA | 1 |
| Foult, JM | 1 |
| Nitenberg, A | 1 |
| Klabunde, RE | 1 |
| Wilcken, DE | 1 |
| Eikens, E | 1 |
| Juhran, W | 1 |
| Voss, EM | 1 |
| Dietmann, K | 1 |
| Schaumann, W | 1 |
| Wadsworth, RM | 2 |
| Parratt, JR | 1 |
| Winbury, MM | 1 |
| Howe, BB | 1 |
| Hefner, MA | 1 |
| Lemieux, VP | 1 |
| Gowdey, CW | 1 |
| Philp, RB | 1 |
| Miura, M | 2 |
| Tominaga, S | 1 |
| Hashimoto, K | 1 |
| Kontos, HA | 1 |
| Goldin, D | 1 |
| Richardson, DW | 1 |
| Patterson, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo[NCT01837108] | Phase 4 | 14 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Is Augmentation of PORH by Rosuvastatin Adenosine-receptor Mediated?[NCT00851175] | Phase 4 | 8 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| Study of Myocardial Perfusion by MRI[NCT00001631] | Phase 2 | 249 participants | Interventional | 1997-08-31 | Completed | ||
| WISE Ancillary Study Data Analyses: Efficacy of Hormone Replacement on Myocardial Ischemia in Postmenopausal Women With Normal/Minimal Coronary Artery Disease: Data Analysis[NCT00600106] | 37 participants (Actual) | Interventional | 1999-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of endothelial dysfunction.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: Baseline
| Intervention | percentage of pre-stimulus diameter (Mean) |
|---|---|
| Hormone Replacement Therapy | 8.2 |
| Placebo | 8.8 |
"Endothelial dysfunction refers to altered vasoactive, anticoagulant, and anti-inflammatory properties of endothelium, and dysregulated vascular growth remodeling that results from a loss of nitric oxide (NO) bioactivity in the endothelium. Brachial Artery Reactivity Testing (BART), high-frequency ultrasonographic imaging of the brachial artery, evaluates flow-mediated vasodilation (FMD), an endothelium-dependent function. The technique provokes the release of nitric oxide, resulting in vasodilation that can be quantitated as an index of vasomotor function.~Flow-mediated vasodilation is typically expressed as the change in post-stimulus diameter as a percentage of the baseline diameter [diameter after cuff deflation - baseline diameter / baseline diameter) x 100]." (NCT00600106)
Timeframe: 12 weeks
| Intervention | percentage of pre-stimulus diameter (Mean) |
|---|---|
| Hormone Replacement Therapy | 8.8 |
| Placebo | 7.3 |
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: 12 weeks
| Intervention | percent change in PCR/ATP ratio (Mean) |
|---|---|
| Hormone Replacement Therapy | -7.7 |
| Placebo | 1.1 |
Inducible myocardial ischemia measured by P-31 gated magnetic resonance cardiac spectroscopy (MRS) is reported as change (∆) in PCr/ATP ratio, with isometric submaximal handgrip stress. PCr/ATP ratio defined as (stress-[average of rest and recovery periods]) / average of rest and recover periods X 100, and expressed as % mean ± SD. For this trial, myocardial ischemia was pre-specified as a fall in quantitative PCR/ATP ratio >20% from rest, and a lower value is considered indicative of greater ischemia. (NCT00600106)
Timeframe: Baseline
| Intervention | percent changed in PCR/ATP ratio (Mean) |
|---|---|
| Hormone Replacement Therapy | -13.8 |
| Placebo | -7.0 |
"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Baseline
| Intervention | mm (Mean) |
|---|---|
| Hormone Replacement Therapy | -0.79 |
| Placebo | -0.79 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Baseline
| Intervention | metabolism equivalents (Mean) |
|---|---|
| Hormone Replacement Therapy | 6.1 |
| Placebo | 5.8 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. (NCT00600106)
Timeframe: Exit (12 weeks)
| Intervention | metabolism equivalents (Mean) |
|---|---|
| Hormone Replacement Therapy | 6.1 |
| Placebo | 5.4 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Baseline
| Intervention | metabolism equivalents (Mean) |
|---|---|
| Hormone Replacement Therapy | 5.4 |
| Placebo | 5.4 |
Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain. A MET is defined as the resting metabolic rate, that is, the amount or oxygen consumet at rest, sitting quietly in a chair, approximately 3.5 ml O2 / kg / min (1.2 kcallmin for a 70-kg person). As such, work at METs requires twice the resting metabolism or 7.0 ml O2/kg/min, and so on. (NCT00600106)
Timeframe: Exit at 12 weeks
| Intervention | metabolism equivalents (Mean) |
|---|---|
| Hormone Replacement Therapy | 6.1 |
| Placebo | 5.4 |
"Physical functional disability measured by exercise stress testing. Functional capacity was measured as metabolism equivalents (METs), exercise duration, and exercise-induced chest pain.~In electrocardiography, the ST segment connects the QRS complex and the T wave and has duration of 80 to 120 ms. It should be essentially level with the PR and TP segment. The normal ST segment has a slight upward concavity. Flat, downsloping, or depressed ST segment may indicate coronary ishcemia. Positive treadmill exercise stress test (>1.0 mm horizontal / downsloping or >1.5 upsloping ST segment depression measured 0.08 msec after the J point)." (NCT00600106)
Timeframe: Exit (12 weeks)
| Intervention | mm (Mean) |
|---|---|
| Hormone Replacement Therapy | -1.05 |
| Placebo | -0.63 |
"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical functioning | Role-physical | Role-emotional | Bodily pain | General health | Mental health | Vitality | Social functioning | |
| Hormone Replacement Therapy | 59.4 | 58.8 | 76.5 | 54.5 | 55.2 | 66.4 | 35.6 | 59.4 |
| Placebo | 44.4 | 25.0 | 66.7 | 41.5 | 57.2 | 69.3 | 41.2 | 56.1 |
"Quality of life assessed by cardiac symptoms and psychological questionnaires (SF 36 scale - Short Form Health Survey) The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions.~Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability." (NCT00600106)
Timeframe: Baseline
| Intervention | units on a scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Physical functioning | Role-physical | Role-emotional | Bodily pain | General health | Mental health | Vitality | Social functioning | |
| Hormone Replacement Therapy | 60.8 | 54.2 | 70.3 | 53.3 | 55.4 | 66.7 | 35.6 | 59.4 |
| Placebo | 43.8 | 37.3 | 66.7 | 42.1 | 57.4 | 65.7 | 42.9 | 53.2 |
Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: 12 weeks
| Intervention | percent of participants (Number) | ||||
|---|---|---|---|---|---|
| Hot flushes or flashing | Poor memory | Change in sexual desire | Vaginal dryness | Avoiding intimacy | |
| Hormone Replacement Therapy | 41 | 59 | 35 | 35 | 24 |
| Placebo | 89 | 78 | 67 | 67 | 56 |
Quality of life assessed by menopausal symptoms and psychological questionnaires (NCT00600106)
Timeframe: Baseline
| Intervention | percent of participants (Number) | ||||
|---|---|---|---|---|---|
| Hot flushes or flashing | Poor memory | Change in sexual desire | Vaginal dryness | Avoiding intimacy | |
| Hormone Replacement Therapy | 89 | 76 | 50 | 44 | 39 |
| Placebo | 68 | 53 | 37 | 58 | 37 |
2 reviews available for dipyridamole and Active Hyperemia
| Article | Year |
|---|---|
Effects of caffeine and theophylline on coronary hyperemia induced by adenosine or dipyridamole.
Topics: Adenosine; Animals; Caffeine; Coronary Circulation; Coronary Disease; Dipyridamole; Drug Administrat | 2009 |
Reactive hyperemia following coronary balloon angioplasty, but not dipyridamole-induced hyperemia, predicts resolution of exercise-induced ST-segment depression.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Circulation; Coronary Di | 2003 |
7 trials available for dipyridamole and Active Hyperemia
| Article | Year |
|---|---|
The effect of eplerenone on adenosine formation in humans in vivo: a double-blinded randomised controlled study.
Topics: Adenosine; Caffeine; Dipyridamole; Double-Blind Method; Eplerenone; Forearm; Hemodynamics; Humans; H | 2014 |
Variability of insulin-stimulated myocardial glucose uptake in healthy elderly subjects.
Topics: Ammonia; Blood Glucose; Dipyridamole; Fluorodeoxyglucose F18; Glucose; Glucose Clamp Technique; Hear | 2002 |
Adenosine transporter antagonism in humans augments vasodilator responsiveness to adenosine, but not exercise, in both adenosine responders and non-responders.
Topics: Adenosine; Adult; Brachial Artery; Dipyridamole; Female; Forearm; Hand Strength; Humans; Hyperemia; | 2007 |
Dipyridamole enhances ischaemia-induced reactive hyperaemia by increased adenosine receptor stimulation.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Dipyridamole; Female; Forearm; Humans; Hyperemia | 2008 |
Safety of early intravenous dipyridamole technetium 99m sestamibi SPECT myocardial perfusion imaging after uncomplicated first myocardial infarction. Early Post MI IV Dipyridamole Study (EPIDS).
Topics: Angina, Unstable; Blood Pressure; Coronary Circulation; Death, Sudden, Cardiac; Dipyridamole; Electr | 1997 |
New noninvasive method for coronary flow reserve assessment: contrast-enhanced transthoracic second harmonic echo Doppler.
Topics: Adult; Aged; Aged, 80 and over; Blood Flow Velocity; Contrast Media; Coronary Angiography; Coronary | 1999 |
Noninvasive assessment of coronary microcirculatory function in postmenopausal women and effects of short-term and long-term estrogen administration.
Topics: Adult; Cold Temperature; Coronary Circulation; Coronary Vessels; Dipyridamole; Estrogen Replacement | 2002 |
65 other studies available for dipyridamole and Active Hyperemia
| Article | Year |
|---|---|
Regadenoson versus dipyridamole: Evaluation of stress myocardial blood flow response on a CZT-SPECT camera.
Topics: Coronary Circulation; Dipyridamole; Humans; Hyperemia; Myocardial Perfusion Imaging; Purines; Pyrazo | 2022 |
Hyperemic stress myocardial perfusion cardiovascular magnetic resonance in mice at 3 Tesla: initial experience and validation against microspheres.
Topics: Animals; Cell Separation; Contrast Media; Coronary Circulation; Dipyridamole; Feasibility Studies; F | 2013 |
Regadenoson versus dipyridamole hyperemia for cardiac PET imaging.
Topics: Adenosine A2 Receptor Agonists; Adult; Aged; Dipyridamole; Female; Heart Diseases; Hemodynamics; Hum | 2015 |
Does a shortened hyperemia with regadenoson stress pose a concern for quantitative Rb-82 PET imaging? Optimization of regadenoson PET imaging.
Topics: Adenosine A2 Receptor Agonists; Dipyridamole; Female; Heart Diseases; Humans; Hyperemia; Male; Posit | 2015 |
Capturing maximal coronary vasodilation for myocardial perfusion imaging: is timing everything?
Topics: Adenosine A2 Receptor Agonists; Dipyridamole; Humans; Hyperemia; Myocardial Perfusion Imaging; Posit | 2015 |
Coronary flow reserve/diastolic function relationship in angina-suffering patients with normal coronary angiography.
Topics: Aged; Biomechanical Phenomena; Blood Flow Velocity; Coronary Angiography; Coronary Vessels; Diastole | 2017 |
Spatial relationship between coronary microvascular dysfunction and delayed contrast enhancement in patients with hypertrophic cardiomyopathy.
Topics: Adolescent; Adult; Aged; Ammonia; Cardiomyopathy, Hypertrophic; Contrast Media; Coronary Circulation | 2008 |
Myocardial blood volume is associated with myocardial oxygen consumption: an experimental study with cardiac magnetic resonance in a canine model.
Topics: Animals; Blood Pressure; Coronary Circulation; Coronary Stenosis; Dipyridamole; Disease Models, Anim | 2009 |
Quantification of regional myocardial oxygenation by magnetic resonance imaging: validation with positron emission tomography.
Topics: Acute Disease; Adrenergic beta-Agonists; Animals; Carbon Radioisotopes; Coronary Circulation; Corona | 2010 |
Improvement of hyperemic myocardial oxygen extraction fraction estimation by a diffusion-prepared sequence.
Topics: Animals; Diffusion; Dipyridamole; Dobutamine; Dogs; Echo-Planar Imaging; Hemodynamics; Hyperemia; My | 2010 |
Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Cell Line; Cell Line, Tumor; Coronary Circulation; Dipy | 2012 |
Physiological basis for angina and ST-segment change PET-verified thresholds of quantitative stress myocardial perfusion and coronary flow reserve.
Topics: Adult; Aged; Angina Pectoris; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; D | 2011 |
PET/CT assessment of symptomatic individuals with obstructive and nonobstructive hypertrophic cardiomyopathy.
Topics: Adult; Aged; Algorithms; Cardiomyopathy, Hypertrophic; Coronary Circulation; Data Interpretation, St | 2012 |
High fat diet-induced glucose intolerance impairs myocardial function, but not myocardial perfusion during hyperaemia: a pilot study.
Topics: Animals; Coronary Circulation; Diet, High-Fat; Dipyridamole; Disease Models, Animal; Glucose Intoler | 2012 |
Plasma asymmetric dimethylarginine and hyperemic myocardial blood flow in young subjects with borderline hypertension or familial hypercholesterolemia.
Topics: Adult; Age Factors; Arginine; Biomarkers; Blood Flow Velocity; Case-Control Studies; Coronary Circul | 2002 |
Myocardial perfusion reserve and peripheral endothelial function in patients with idiopathic dilated cardiomyopathy.
Topics: Brachial Artery; Cardiomyopathy, Dilated; Case-Control Studies; Coronary Circulation; Dipyridamole; | 2004 |
Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole.
Topics: Adenosine Triphosphate; Adult; Caffeine; Coronary Circulation; Dipyridamole; Heart; Hemodynamics; Hu | 2004 |
Incremental benefit of myocardial contrast to combined dipyridamole-exercise stress echocardiography for the assessment of coronary artery disease.
Topics: Aged; Comorbidity; Contrast Media; Coronary Angiography; Coronary Circulation; Coronary Disease; Dip | 2004 |
The influence of hepatic lipase C-480T polymorphism on coronary flow reserve in young men is independent of the plasma cholesterol level.
Topics: Adenosine; Adult; Cholesterol; Coronary Circulation; Dipyridamole; Genotype; Humans; Hyperemia; Lipa | 2006 |
Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene.
Topics: Adult; AMP Deaminase; Dipyridamole; Female; Forearm; Humans; Hyperemia; Ligation; Male; Reperfusion | 2007 |
Detection of moderate regional ischemia in pig hearts in vivo by near-infrared and thermal imaging: effects of dipyridamole.
Topics: Animals; Blood Pressure; Body Temperature; Coronary Circulation; Coronary Vessels; Dipyridamole; Dis | 2008 |
Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilation. VI. Detection of coronary artery disease in human beings with intravenous N-13 ammonia and positron computed tomography.
Topics: Adolescent; Adult; Aged; Ammonia; Coronary Disease; Coronary Vessels; Dipyridamole; Female; Humans; | 1982 |
Phasic coronary blood flow velocity in intramural and epicardial coronary arteries.
Topics: Animals; Arterial Occlusive Diseases; Blood Flow Velocity; Cardiac Pacing, Artificial; Coronary Circ | 1982 |
Role of adenosine in local control of intestinal circulation in the dog.
Topics: Adenosine; Animals; Blood Flow Velocity; Dipyridamole; Dogs; Fasting; Food; Homeostasis; Hyperemia; | 1980 |
Effects of modified pharmacologic stress approaches on hyperemic myocardial blood flow.
Topics: Adult; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Coronary Vessels; Dipyridamole; | 1995 |
Quantitative demonstration of dipyridamole-induced coronary steal and alteration by angioplasty in man: analysis by simultaneous, continuous dual Doppler spectral flow velocity.
Topics: Adenosine; Aminophylline; Angioplasty, Balloon, Coronary; Blood Flow Velocity; Coronary Artery Disea | 1993 |
Contrast-enhanced first pass myocardial perfusion imaging: correlation between myocardial blood flow in dogs at rest and during hyperemia.
Topics: Animals; Contrast Media; Coronary Circulation; Coronary Disease; Dipyridamole; Dogs; Gadolinium; Gad | 1993 |
Myocardial intensity changes associated with flow stimulation in blood oxygenation sensitive magnetic resonance imaging.
Topics: Adult; Blood Flow Velocity; Blood Pressure; Contrast Media; Coronary Circulation; Coronary Vessels; | 1996 |
Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET.
Topics: Adenosine; Adult; Ammonia; Coronary Circulation; Dipyridamole; Female; Hemodynamics; Humans; Hyperem | 1996 |
Effect of alpha 1-adrenoceptor blockade on resting and hyperemic myocardial blood flow in normal humans.
Topics: Adrenergic alpha-Antagonists; Aged; Coronary Circulation; Dipyridamole; Doxazosin; Female; Hemodynam | 1996 |
Correlation between hemodynamic changes and tomographic sestamibi imaging during dipyridamole-induced coronary hyperemia.
Topics: Adult; Aged; Blood Pressure; Coronary Angiography; Coronary Disease; Dipyridamole; Female; Heart Dis | 1998 |
Prognostic value of myocardial perfusion imaging with exercise and/or dipyridamole hyperemia in patients with preexisting left bundle branch block.
Topics: Adult; Aged; Aged, 80 and over; Bundle-Branch Block; Coronary Circulation; Dipyridamole; Exercise Te | 1998 |
Impaired myocardial vasodilation during hyperemic stress with dipyridamole in hypertriglyceridemia.
Topics: Adult; Coronary Circulation; Dipyridamole; Electrocardiography; Exercise Test; Female; Heart; Heart | 1998 |
Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy.
Topics: Adult; Aged; Cardiomyopathy, Dilated; Coronary Circulation; Dipyridamole; Energy Metabolism; Female; | 2000 |
Myocardial flow reserve parametric map, assessed by first-pass MRI compartmental analysis at the chronic stage of infarction.
Topics: Aged; Collateral Circulation; Coronary Circulation; Dipyridamole; Exercise Test; Female; Humans; Hyp | 2001 |
Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aging; Coronary Circulation; Dipyridamole; Female; Heart; | 2001 |
Peripheral and myocardial microcirculation.
Topics: Brachial Artery; Coronary Circulation; Coronary Vessels; Dipyridamole; Forearm; Humans; Hyperemia; M | 2001 |
Effect of dipyridamole on myocardial adenosine metabolism and coronary flow in hypoxia and reactive hyperemia in the isolated perfused guinea pig heart.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Cardiome | 1976 |
ATP is released into the rabbit eye by antidromic stimulation of the trigeminal nerve.
Topics: Adenosine Triphosphate; Animals; Aqueous Humor; Dipyridamole; Hyperemia; Intraocular Pressure; Male; | 1979 |
Effects of radiopaque material on coronary vascular reserve.
Topics: Animals; Contrast Media; Coronary Circulation; Coronary Vessels; Diatrizoate; Dipyridamole; Dogs; He | 1975 |
Role of adenosine in postprandial and reactive hyperemia in canine jejunum.
Topics: Adenosine; Adenosine Deaminase; Animals; Arterial Occlusive Diseases; Blood Volume; Dipyridamole; Do | 1992 |
What is the optimum dose of dipyridamole for cardiac imaging?
Topics: Coronary Disease; Dipyridamole; Echocardiography; Electrocardiography; Humans; Hyperemia; Myocardial | 1992 |
Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.
Topics: Albumins; Animals; Contrast Media; Coronary Circulation; Coronary Disease; Diagnosis, Differential; | 1992 |
Interpretation of cardiac pathophysiology from pressure waveform analysis: coronary hemodynamics, Part III: Coronary hyperemia.
Topics: Adenosine; Blood Flow Velocity; Cardiac Catheterization; Contrast Media; Coronary Circulation; Coron | 1992 |
Relationship between coronary blood flow and perfusion pressure during reactive hyperemia: a case report in an awake unanesthetized woman with normal coronary arteries.
Topics: Aged; Blood Flow Velocity; Blood Pressure; Coronary Circulation; Dipyridamole; Echocardiography, Dop | 1991 |
Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium.
Topics: Acetates; Animals; Carbon Dioxide; Carbon Radioisotopes; Coronary Circulation; Dipyridamole; Dogs; H | 1990 |
Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.
Topics: Animals; Coronary Circulation; Coronary Disease; Dipyridamole; Dogs; Female; Hyperemia; Male; Pentox | 1990 |
Thyroxine-induced left ventricular hypertrophy in the rat. Anatomical and physiological evidence for angiogenesis.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Body Weight; Capillaries; Cardiomegaly; Coronary Circu | 1985 |
Assessment of regional myocardial perfusion by contrast echocardiography. II. Detection of changes in transmural and subendocardial perfusion during dipyridamole-induced hyperemia in a model of critical coronary stenosis.
Topics: Animals; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Dipyridamole; Disease Models, | 1989 |
MRI detection of myocardial perfusion changes by gadolinium-DTPA infusion during dipyridamole hyperemia.
Topics: Animals; Contrast Media; Coronary Circulation; Coronary Disease; Dipyridamole; Disease Models, Anima | 1989 |
Cardiac imaging and myocardial kinetics of technetium-tertiary butyl-isonitrile during dipyridamole-induced hyperemia.
Topics: Animals; Coronary Circulation; Coronary Disease; Dipyridamole; Dogs; Heart; Hyperemia; Microspheres; | 1988 |
Thallium-201 myocardial scintigraphy during dipyridamole-induced coronary hyperaemia. First experiences with a new regional washout programme.
Topics: Aged; Aged, 80 and over; Aorta, Abdominal; Coronary Vessels; Dipyridamole; Female; Heart; Humans; Hy | 1988 |
Myocardial reactive hyperemia in the newborn.
Topics: Adenosine; Cerebrovascular Circulation; Dipyridamole; Humans; Hyperemia; Infant, Newborn; Myocardium | 1988 |
Myocardial uptake and clearance of thallium-201 in normal subjects: comparison of dipyridamole-induced hyperemia with exercise stress.
Topics: Adult; Dipyridamole; Female; Hemodynamics; Humans; Hyperemia; Kinetics; Male; Myocardium; Physical E | 1987 |
Dipyridamole versus intracoronary injection of contrast medium for the evaluation of coronary reserve in man: a comparative study.
Topics: Adult; Contrast Media; Coronary Circulation; Dipyridamole; Female; Humans; Hyperemia; Infusions, Int | 1986 |
Conditions for dipyridamole potentiation of skeletal muscle active hyperemia.
Topics: Animals; Blood Vessels; Dipyridamole; Dogs; Female; Hyperemia; Isometric Contraction; Male; Muscles; | 1986 |
Reactive hyperaemia in the dog heart: studies on mechanisms.
Topics: Adenosine; Aminophylline; Animals; Blood Pressure; Coronary Circulation; Dipyridamole; Dogs; Heart R | 1974 |
Pharmacological effects on coronary reactive hyperemia in conscious dogs.
Topics: Animals; Coronary Disease; Coronary Vessels; Coumarins; Dipyridamole; Dogs; Drug Synergism; Glycolat | 1971 |
Anti-anginal drugs and the vasodilator response to myocardial hypoxia.
Topics: Angina Pectoris; Animals; Cats; Collateral Circulation; Coronary Circulation; Dipyridamole; Drug Syn | 1971 |
The effects of dipyridamole on coronary post-occlusion hyperaemia and on myocardial vasodilatation induced by systemic hypoxia.
Topics: Animals; Benzoates; Blood Pressure; Catheterization; Cats; Coronary Vessels; Dipyridamole; Electroca | 1972 |
Effect of nitrates and other coronary dilators on large and small coronary vessels: an hypothesis for the mechanism of action of nitrates.
Topics: Aminophylline; Animals; Aorta; Biophysical Phenomena; Biophysics; Blood Circulation; Blood Flow Velo | 1969 |
Effects of dipyridamole and nitroprusside on the oxygen paradox and reactive hyperemia.
Topics: Animals; Blood Pressure; Carotid Arteries; Cats; Dipyridamole; Femoral Artery; Ferricyanides; Hypere | 1970 |
[Pharmacological study on reactive hyperemia in the coronary and femoral circulation--mechanism of the blood flow regulation in the myocardium and skeletal muscles].
Topics: Acetylcholine; Animals; Bradykinin; Cardiac Output; Coronary Vessels; Dipyridamole; Dogs; Femoral Ar | 1967 |
Potentiation of reactive hyperemia in the coronary and femoral circulation by the selective use of 2,6-bis(diethanolamino)-4,8-dipiperidino-pyrimodo[5,4-d]pyrimidine.
Topics: Acetylcholine; Animals; Blood Circulation; Bradykinin; Coronary Vessels; Dipyridamole; Dogs; Drug Sy | 1967 |
Effect of dipyridamole on vasodilator responses to ischemia, hypoxia, ATP, and AMP.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Blood Pressure; Blood Vessels; Dipyridamole; D | 1968 |